

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Ranibizumab for the treatment of choroidal neovascularisation
associated with pathological myopia**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

- a) There is higher prevalence of the condition in people of working age.
- b) There is inequity in access to treatment with ranibizumab for people on low income.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

- a) The perspective of the reference case on cost should be that of the NHS and Personal Social Service. Societal benefits gained from any additional productivity in people of working age is therefore outside the current remit of a NICE appraisal.
 - b) The issue raised falls outside the population protected by the equality legislation and it is not expected that an appraisal of ranibizumab will impose any restrictions in terms of the access to treatment for people on low income.
- No change required to the scope.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No change required to the scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): Frances Sutcliffe

Date: 06 02 2013